ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Biotechnological potential of Paenarthrobacter nicotinovorans ATCC 49919 for the microbial conversion of nicotine and tobacco extracts into 6-hydroxynicotine.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nicotine-rich wastes from the tobacco industry represent an environmental liability but also a potential feedstock for value-added bioconversion. In this study, the biotechnological potential of Paenarthrobacter nicotinovorans ATCC 49919 for selective accumulation of 6-hydroxy-(L)-nicotine (6HLN), the first intermediate of the pyridine pathway, was evaluated under flask and bioreactor conditions. Two metabolic engineering strategies were explored: transcriptional silencing of the 6-hydroxynicotine oxidase gene (6hlnO) using a CRISPR/dCas9 system and overexpression of the nicotine dehydrogenase large subunit (ndhL) to enhance entry flux into the pathway. Among the tested strains, the ndhL-overexpressing derivative exhibited the highest 6HLN accumulation during growth (up to 1.78 g L⁻
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.